VivoSeq
Other

Infliximab

0

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Infliximab is an early-stage landscape with 0 programs across 3 companies. The most active players are Merck & Co., Pfizer, Taizhou Mabtech Pharmaceutical Co.,Ltd.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

45/100

Attrition Rate

44/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalT

Taizhou Mabtech Pharmaceutical Co.,Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

25

clinical trials

Completed9 · 36%
Terminated8 · 32%
Unknown status3 · 12%
Withdrawn3 · 12%
Recruiting2 · 8%

Clinical Trials

Trial Activity

25 trials

Precise Infliximab Exposure and Pharmacodynamic Control
Recruiting·—·Phase 2/3·NCT05660746·180 enrolled
Topical Infliximab for Sterile Corneal Melt
Recruiting·—·Phase 1·NCT02987686·12 enrolled
A 6-Months Infliximab Or Placebo Study In UA At High Risk Of RA:Clinical,Radiological And Synovial Benefit
Completed·—·N/A·NCT01245361·30 enrolled
The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety
Completed·TTaizhou Mabtech Pharmaceutical Co.,Ltd·Phase 1·NCT04779892·90 enrolled
A Long-term Safety Study of Infliximab (Remicade)
Completed·CCentocor, Inc.·N/A·NCT00261976·2,971 enrolled
CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects
Completed·CCelltrion·Phase 1·NCT03446976·218 enrolled
RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT00307593·20 enrolled
Efficacy, Safety, and Tolerability Study of Infliximab in Juvenile Spondyloarthropathies
Completed·HHospital General de Mexico·Phase 2/3·NCT00591201·26 enrolled
A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)
Completed·Pfizer logoPfizer·Phase 1·NCT01844804·146 enrolled
Safety of Reduced Infliximab Infusion Time
Completed·WWashington University School of Medicine·Phase 4·NCT05340764·96 enrolled
Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab
Completed·—·Phase 4·NCT02453776·80 enrolled
Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440)
Terminated·Merck & Co. logoMerck & Co.·Phase 4·NCT00686894·7 enrolled
Infliximab Accelerated Induction in Moderate to Severe Pediatric UC
Terminated·SSchneider Children's Medical Center, Israel·N/A·NCT03209232·10 enrolled
The HAM Infliximab Study
Terminated·IImperial College London·Phase 2·NCT00823641·3 enrolled
Infliximab Top-down in Pediatric Crohn
Terminated·EErasmus Medical Center·Phase 4·NCT01880307·13 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)